{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:12:54Z","timestamp":1790817174426,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100019271","name":"Kyorin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe real\u2010world initial pharmacotherapy, treatment persistence, and diagnostic testing for overactive bladder in Japan by medical specialty and facility type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective descriptive study used nationwide administrative claims data. Patients aged 15\u2009years or older diagnosed with overactive bladder in 2022 who newly initiated pharmacotherapy were followed for 1\u2009year. Analyses were conducted across four groups defined by medical specialty and facility type. We summarized initial medication, baseline comorbidities, one\u2010year treatment persistence, and performance of urinalysis and postvoid residual volume measurement at diagnosis and within 1\u20133\u2009months thereafter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 702\u2009078 patients diagnosed with overactive bladder, 65 173 met the eligibility criteria (median age 80\u2009years; interquartile range 74.0\u201385.0; women 56.3%). \u03b23\u2010adrenoceptor agonists accounted for more than 70% of initial prescriptions in both urology and internal medicine, whereas anticholinergics were used more often in internal medicine than in urology. Baseline comorbidities, including dementia, were broadly similar between patients initiating \u03b23\u2010adrenoceptor agonists and those initiating anticholinergics, except for benign prostatic hyperplasia. At 1\u2009year, persistence was higher for \u03b23\u2010adrenoceptor agonists than for anticholinergics and other drugs, but remained below 30% for \u03b23\u2010adrenoceptor agonists. Urinalysis and postvoid residual volume measurement were performed more frequently in urology than in internal medicine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\u03b23\u2010adrenoceptor agonists predominated as initial pharmacotherapy for overactive bladder in Japan, whereas anticholinergics were used more often in internal medicine than in urology. Similar comorbidity profiles and specialty\u2010related differences in diagnostic testing highlight opportunities to optimize individualized prescribing and strengthen guideline\u2010concordant evaluation across care settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/iju.70468","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:20:19Z","timestamp":1776777619000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prescribing Patterns and Treatment Persistence for Overactive Bladder in Japan Across Medical Specialties and Facility Types: A Nationwide Claims Database Study"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0109-7425","authenticated-orcid":false,"given":"Kenji","family":"Omae","sequence":"first","affiliation":[{"name":"Department of Innovative Research and Education for Clinicians and Trainees (DiRECT), Fukushima Medical University Hospital  Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Medical Affairs, Kyorin Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0750-2172","authenticated-orcid":false,"given":"Shotaro","family":"Maeda","sequence":"additional","affiliation":[{"name":"Medical Affairs, Kyorin Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15454"},{"key":"e_1_2_12_3_1","first-page":"1183","article-title":"The Demographics and Treatment Circumstances of Patients Receiving OAB Treatment Medication","volume":"27","author":"Yamagami H.","year":"2024","journal-title":"Japanese Journal of Urology Surgery"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2012.04.004"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000459"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2020.08.037"},{"key":"e_1_2_12_7_1","volume-title":"Clinical Guidelines for Overactive Bladder Syndrome 3rd Edition","author":"The Japanese Continence Society, The Japanese Urological Association","year":"2022"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1376535"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58060825"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2025.10.011"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03070-x"},{"key":"e_1_2_12_12_1","unstructured":"Medical and healthcare database utilization committee Japanese Society for Pharmacoepidemiology \u201cSurvey of Japanese Databases in Japan Available for Clinical\/Pharmacoepidemiology \u201d(2025) https:\/\/www.jspe.jp\/committee\/kenkou\u2010iryou\/."},{"key":"e_1_2_12_13_1","unstructured":"RECORD \u201cRECORD Reporting Guidelines (REporting of Studies Conducted Using Observational Routinely\u2010Collected Health Data) \u201d(2015) https:\/\/www.record\u2010statement.org\/."},{"key":"e_1_2_12_14_1","unstructured":"Ministry of Education Culture Sports Science and Technology (Japan) Ministry of Health Labour and Welfare (Japan) andMinistry of Economy Trade and Industry (Japan) \u201cEthical Guidelines for Medical and Biological Research Involving Human Subjects \u201d(2021) https:\/\/www.mhlw.go.jp\/content\/001457376.pdf."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.70036"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.020"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-08546-4"},{"key":"e_1_2_12_18_1","volume-title":"Guidelines for Medical Treatment and Its Safety in the Elderly 2025","author":"Japan Geriatrics Society","year":"2025"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12148"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12535"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.3098"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12151"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12391"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25416"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.70468","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:52:10Z","timestamp":1777027930000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.70468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/iju.70468"],"URL":"https:\/\/doi.org\/10.1111\/iju.70468","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2026-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70468"}}